Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Rhythm Pharmaceuticals (RYTM)
:RYTM
RESEARCH TOOLSreports
Holding RYTM?
Track your performance easily
RYTM Stock Chart & Stats
Day’s Range― - ―
52-Week Range$35.17 - $68.58
Previous CloseN/A
Volume91.33K
Average Volume (3M)543.26K
Market Cap
$3.36B
Enterprise Value$3.16B
Total Cash (Recent Filing)$10.54M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.08
Next Earnings
Mar 04, 2025EPS Estimate
-0.69Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.34
Shares Outstanding61,457,070
10 Day Avg. Volume527,065
30 Day Avg. Volume543,260
Standard Deviation0.35
R-Squared0.10
Alpha0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)29.85
Price to Cash Flow (P/CF)-33.30
P/FCF Ratio0.00
Enterprise Value/Market Cap0.94
Enterprise Value/Revenue28.11
Enterprise Value/Gross Profit46.44
Enterprise Value/Ebitda-15.49
Forecast
1Y Price Target
$71.92Price Target Upside31.58% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
Rhythm Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Clinical AdvancementsThe company announced it plans to begin an exploratory 26-week, open-label Phase 2 trial in Prader-Willi syndrome (PWS), evaluating 20 patients with PWS and obesity.
Financial PerformanceRhythm Pharmaceutical pre-announced 4Q24 and FY24 Imcivree revenues ahead of expectations.
Regulatory MilestonesThe FDA has approved an expanded indication for IMCIVREE to include children as young as two years of age.
Bears Say
Intellectual PropertyExpectations are already high and there's not enough time to fully capitalize and get to peak revenue if intellectual property expires in 2032.
Market DevelopmentDevelopment in the congenital HO population is still early with outstanding commercial uncertainties on the exact prevalence of the patient population, number of diagnosed patients, and the proportion with obesity.
Market ValuationCurrent $3-4B market cap already prices in a positive study and launch, which limits immediate upside potential.
---
Ownership Overview
0.57% Insiders
26.31% Mutual Funds
0.31% Other Institutional Investors
60.92% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RYTM FAQ
What was Rhythm Pharmaceuticals’s price range in the past 12 months?
Rhythm Pharmaceuticals lowest stock price was $35.17 and its highest was $68.58 in the past 12 months.
What is Rhythm Pharmaceuticals’s market cap?
Rhythm Pharmaceuticals’s market cap is $3.36B.
When is Rhythm Pharmaceuticals’s upcoming earnings report date?
Rhythm Pharmaceuticals’s upcoming earnings report date is Mar 04, 2025 which is in 45 days.
How were Rhythm Pharmaceuticals’s earnings last quarter?
Rhythm Pharmaceuticals released its earnings results on Nov 05, 2024. The company reported -$0.73 earnings per share for the quarter, beating the consensus estimate of -$0.805 by $0.075.
Is Rhythm Pharmaceuticals overvalued?
According to Wall Street analysts Rhythm Pharmaceuticals’s price is currently Undervalued.
Does Rhythm Pharmaceuticals pay dividends?
Rhythm Pharmaceuticals does not currently pay dividends.
What is Rhythm Pharmaceuticals’s EPS estimate?
Rhythm Pharmaceuticals’s EPS estimate is -0.69.
How many shares outstanding does Rhythm Pharmaceuticals have?
Rhythm Pharmaceuticals has 61,457,070 shares outstanding.
What happened to Rhythm Pharmaceuticals’s price movement after its last earnings report?
Rhythm Pharmaceuticals reported an EPS of -$0.73 in its last earnings report, beating expectations of -$0.805. Following the earnings report the stock price went up 11.378%.
Which hedge fund is a major shareholder of Rhythm Pharmaceuticals?
Currently, no hedge funds are holding shares in RYTM
---
Rhythm Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$71.92 (31.58% Upside)
$71.92 (31.58% Upside)
Blogger Sentiment
Bullish
RYTM Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 243.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.7%
Last 30 Days ▲ 18.5%
Last 30 Days ▲ 18.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
30.72%
12-Months-Change
Fundamentals
Return on Equity
-248.12%
Trailing 12-Months
Asset Growth
2.65%
Trailing 12-Months
Company Description
Rhythm Pharmaceuticals
Rhythm Pharmaceuticals, Inc. develops and commercializes peptide therapeutics for the treatment of gastrointestinal diseases and genetic deficiencies. It focuses on the treatment for Prader-Willi Syndrome and Pro-Opiomelanocortin deficiency obesity. The firm rapidly develops setmelanotide for rare genetic disorders of obesity caused by MC4 pathway deficiencies and provides advance setmelanotide for POMC deficiency obesity and LEPR deficiency obesity as first indications in upstream MC4 pathway deficiencies. The company was founded by Bart Henderson in February 2010 and is headquartered in Boston, MA.
---
RYTM Company Deck
---
RYTM Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a generally positive outlook with steady revenue growth, significant international expansion, and promising clinical data, particularly in hypothalamic obesity. However, challenges remain in managing high expenses and patient retention.Read More>---
RYTM Stock 12 Month Forecast
Average Price Target
$71.92
▲(31.58% Upside)
Technical Analysis
Immunovant
―
BioCryst
―
Kiniksa Pharmaceuticals
―
FibroGen
―
Blueprint Medicines
―
Seres Therapeutics
―
Best Analysts Covering RYTM
1 Year
1 Year Success Rate
14/16 ratings generated profit
1 Year Average Return
+56.74%
reiterated a buy rating last month
Copying Corinne Johnson's trades and holding each position for 1 Year would result in 87.50% of your transactions generating a profit, with an average return of +56.74% per trade.
---